Frigo speaks, teaches and consults globally, advising organizations seeking to become high performance companies. Frigo is co-creator of the revolutionary Return Driven Strategy framework which is used by corporate management teams, boards of directors and money managers to make the connection between a company's business plans and market valuation. He is an advisor to boards of directors and executive teams.
For more information, please visit www.ziotwinturthucdi.cf/receptor-mediated-uptake-in-the-liver.php
Ep. 16: Dr. Mark Frigo - Leadership Driven Strategy
Strategy Risk Management Lab. Targeting the 5'-AMP-activated protein kinase and related metabolic pathways for the treatment of prostate cancer. Expert Opin Ther Targets 19 5 , Oncogene 33 45 , Regulation of the pentose phosphate pathway by an androgen receptor-mTOR-mediated mechanism and its role in prostate cancer cell growth. Oncogenesis 3:e, Androgens promote prostate cancer cell growth through induction of autophagy. Mol Endocrinol 27 2 , Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.
J Clin Invest 1 , Antiestrogenic activity of flavonoid phytochemicals mediated via the c-Jun N-terminal protein kinase pathway. Cell-type specific regulation of estrogen receptor alpha. J Steroid Biochem Mol Biol , Environ Health Perspect 9 , J Endocrinol 1 , CaM kinase kinase beta-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells.
Cancer Res 71 2 , Induction of Kruppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cells in vitro.
Mol Endocrinol 23 9 , Glucose metabolism as a target of histone deacetylase inhibitors. Mol Endocrinol 23 3 , Organochlorine-mediated potentiation of the general coactivator p through p38 mitogen-activated protein kinase.
Dr. Christopher Frigo, DDS
Carcinogenesis 30 1 , Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic. Cancer Res 68 18 , Differential effects of prostate cancer therapeutics on neuroendocrine transdifferentiation.
- Request an Appointment.
- Citations per year.
- See a Problem?.
- World Smile Day :: Dr. Frigo’s 30 Minute Rule.
Mol Cancer Ther 7 3 , AKT regulation of estrogen receptor beta transcriptional activity in breast cancer. Cancer Res 66 17 , Mol Endocrinol 20 5 , Toxicol Lett 2 , Mark L.
Driving Long-Term, Sustainable Value – The Role of the CFO-Dr Mark Fr…
Author of six books and over articles, his work is published in leading business journals including Harvard Business Review. His professional career has included corporate strategic planning, corporate mergers and acquisitions and management consulting at KPMG. In the area of strategic valuation, Dr.
Related Dr. Frigo
Copyright 2019 - All Right Reserved